Joseph L. Goldstein's most recent trade in Regeneron Pharmaceuticals, Inc. was a trade of 1,962 Non-Qualified Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regeneron Pharma | Joseph L. Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 1,962 | 1,962 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Joseph L. Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 155 | 6,703 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | Joseph L. Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 1,958 | 1,958 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Joseph L. Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 166 | 6,548 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | L. Joseph Goldstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 625.60 per share. | 23 Jan 2024 | 2,707 | 9,089 (0%) | 0% | 625.6 | 1,693,499 | Common Stock |
| Regeneron Pharma | Joseph Goldstein L. | Director | Sale of securities on an exchange or to another person at price $ 950.00 per share. | 23 Jan 2024 | 2,707 | 6,382 (0%) | 0% | 950 | 2,571,650 | Common Stock |
| Regeneron Pharma | Joseph Goldstein L. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2024 | 2,707 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Goldstein Joseph L. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 1,607 | 1,607 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Goldstein L. Joseph | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 135 | 6,382 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | Joseph L. Goldstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2023 | 3,613 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Joseph L. Goldstein | Director | Sale of securities on an exchange or to another person at price $ 800.00 per share. | 06 Feb 2023 | 3,613 | 6,247 (0%) | 0% | 800 | 2,890,400 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 482.68 per share. | 06 Feb 2023 | 3,613 | 9,860 (0%) | 0% | 482.7 | 1,743,923 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 1,929 | 1,929 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Joseph L. Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 165 | 6,247 (0%) | 0% | 0 | Common Stock | |
| Regeneron Pharma | Joseph L. Goldstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 374.12 per share. | 30 Mar 2022 | 2,431 | 8,513 (0%) | 0% | 374.1 | 909,486 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2022 | 2,431 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Joseph L. Goldstein | Director | Sale of securities on an exchange or to another person at price $ 700.00 per share. | 30 Mar 2022 | 2,431 | 6,082 (0%) | 0% | 700 | 1,701,700 | Common Stock |
| Regeneron Pharma | Joseph L. Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 2,707 | 2,707 | - | - | Non-Qualified Stock Option (right to buy) | |
| Regeneron Pharma | Joseph L. Goldstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 191 | 6,082 (0%) | 0% | 0 | Common Stock |